Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)

Reuters

Feb 19

Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)

Biotricity reported Q3 FY2026 results (ended Dec. 31, 2025) with revenue of USD 4 million (+10.2%) and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring (TaaS) Technology Fees rose to USD 3.6 million (+7.4%) and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-007369), on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612942782"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612942782\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612942782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 06:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612942782","market":"fut","top_or_hot":-1,"title":"Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biotricity reported Q3 FY2026 results (ended Dec. 31, 2025) with revenue of USD 4 million (+10.2%) and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring (TaaS) Technology Fees rose to USD 3.6 million (+7.4%) and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BTCY\">Biotricity Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-007369), on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-19 06:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biotricity reported Q3 FY2026 results (ended Dec. 31, 2025) with revenue of USD 4 million (+10.2%) and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring (TaaS) Technology Fees rose to USD 3.6 million (+7.4%) and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BTCY\">Biotricity Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-007369), on February 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL74Zpwq:1","article_id":"2612942782","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612942782","pubTimestamp":1771453915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biotricity reported Q3 FY2026 results  with revenue of USD 4 million  and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring  Technology Fees rose to USD 3.6 million  and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news br","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","BTCY":"Biotricity Inc."},"translate_title":"Biotricity 2026财年第三季度毛利率增长81.5%(+5.1%)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTCY":0.9},"content_text":"Biotricity Q3 FY2026 gross margin rises 81.5% (+5.1%)\n    \n\n        Biotricity reported Q3 FY2026 results (ended Dec. 31, 2025) with revenue of USD 4 million (+10.2%) and gross margin of 81.5%. Net loss narrowed to USD 1.1 million, or USD 0.042 per share. Recurring (TaaS) Technology Fees rose to USD 3.6 million (+7.4%) and represented 91.2% of Q3 FY2026 revenue. The company cited 90+% customer retention, app users scaling to more than 44,000 from 4,500 over two years, and a network of over 2,500 providers supporting 4,000,000 patients annually. Biotricity also said it is on track to obtain FDA clearance for its AI clinical model in the coming months and noted international approvals in Canada, Saudi Arabia, and Argentina.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biotricity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-007369), on February 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}